Nuveen
CORT icon

Nuveen’s Corcept Therapeutics CORT Stock Holding History

Nuveen’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.7M Buy
388,078
+196,174
+102% +$11.8M 0.01% 941
2026
Q1 		$7.74M Buy
191,904
+5,379
+3% +$201K ﹤0.01% 1696
2025
Q4 		$6.49M Hold
186,525
– – ﹤0.01% 1790
2025
Q3 		$15.5M Buy
186,525
+30,494
+20% +$2.21M ﹤0.01% 1296
2025
Q2 		$11.5M Sell
156,031
-155,472
-50% -$11.3M ﹤0.01% 1436
2025
Q1 		$35.6M Buy
311,503
+90,824
+41% +$5.53M 0.01% 777
2024
Q4 		$11.1M Sell
220,679
-1,401
-0.6% -$73.4K ﹤0.01% 1538
2024
Q3 		$10.3M Sell
222,080
-1,285
-0.6% -$45.7K ﹤0.01% 1584
2024
Q2 		$7.26M Buy
223,365
+4,328
+2% +$119K ﹤0.01% 1757
2024
Q1 		$5.52M Sell
219,037
-44,354
-17% -$1.05M ﹤0.01% 1939
2023
Q4 		$8.55M Buy
263,391
+5,011
+2% +$138K ﹤0.01% 1695
2023
Q3 		$7.04M Sell
258,380
-20,266
-7% -$587K ﹤0.01% 1684
2023
Q2 		$6.2M Buy
278,646
+31,594
+13% +$727K ﹤0.01% 1794
2023
Q1 		$5.35M Sell
247,052
-7,006
-3% -$154K ﹤0.01% 1848
2022
Q4 		$5.16M Sell
254,058
-8,986
-3% -$225K ﹤0.01% 1888
2022
Q3 		$6.74M Sell
263,044
-162,954
-38% -$4.36M ﹤0.01% 1714
2022
Q2 		$10.1M Buy
425,998
+72,237
+20% +$1.57M ﹤0.01% 1503
2022
Q1 		$8.71M Buy
353,761
+65,122
+23% +$1.39M ﹤0.01% 1738
2021
Q4 		$5.58M Sell
288,639
-51,520
-15% -$1.05M ﹤0.01% 2050
2021
Q3 		$6.7M Sell
340,159
-42,776
-11% -$895K ﹤0.01% 2060
2021
Q2 		$8.43M Sell
382,935
-57,467
-13% -$1.28M ﹤0.01% 1973
2021
Q1 		$10.5M Buy
440,402
+2,314
+0.5% +$61.8K ﹤0.01% 1768
2020
Q4 		$11.5M Buy
438,088
+410
+0.1% +$8.64K ﹤0.01% 1620
2020
Q3 		$7.62M Sell
437,678
-209,925
-32% -$3.35M ﹤0.01% 1682
2020
Q2 		$10.9M Buy
647,603
+4,468
+0.7% +$62.8K ﹤0.01% 1428
2020
Q1 		$7.65M Buy
643,135
+187,239
+41% +$2.32M ﹤0.01% 1458
2019
Q4 		$5.52M Sell
455,896
-62,262
-12% -$867K ﹤0.01% 1939
2019
Q3 		$7.32M Sell
518,158
-4,620
-0.9% -$56.8K ﹤0.01% 1752
2019
Q2 		$5.83M Buy
+522,778
New +$5.83M ﹤0.01% 1892

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's CORT Position: Q2 2026 in Review

Nuveen increased its Corcept Therapeutics (CORT) stake by 102% in Q2 2026, buying an estimated $11.8M and bringing the position to 388,078 shares worth $33.7M. The position accounts for 0.01% of the portfolio, ranked #941.

Nuveen first reported a position in CORT in Q2 2019 and has held it in 29 quarters since. The position peaked at $35.6M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Nuveen held 388,078 shares of Corcept Therapeutics worth $33.7M as of Q2 2026.
  • Nuveen bought 196,174 Corcept Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Corcept Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #941 holding.
  • Nuveen first reported a position in Corcept Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Corcept Therapeutics position peaked at $35.6M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.